Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

A Multi-center, Randomized, Controlled Trial Evaluating the Effects of Early High-Dose Cryoprecipitate in Adult Patients With Major Trauma Hemorrhage Requiring Major Hemorrhage Protocol (MHP) Activation

The purpose of this trial is to compare standard of care (SOC) massive transfusion protocol to SOC massive transfusion protocol plus early use of cryoprecipitate (within 90 minutes of emergency department arrival).

Inclusion Criteria:

• The patient is judged to be an adult (according to local practice, e.g. 16 years or older in UK) and has sustained severe traumatic injury. In the event the age is unknown, estimated body weight ≥50 kg.
• The patient is deemed by the attending clinician to have on-going active hemorrhage AND REQUIRES Activation of the local major hemorrhage protocol for management of severe blood loss AND HAS STARTED or HAS RECEIVED at least one unit of any blood component

Exclusion Criteria:

• The patient has been transferred from another hospital
• The trauma team leader deems the injuries incompatible with life
• More than 3 hours have elapsed from the time of injury
• Prisoner (as defined as someone admitted from a correctional facility)
• Known "Do Not Resuscitate" orders
• Enrolled in a concurrent ongoing interventional, randomized clinical trial
• Patients who wear "opt out" bracelet for study
• Obvious pregnancy
• Severely burned